Published by Global Banking & Finance Review®
Posted on September 15, 2025
1 min readLast updated: January 21, 2026
Add as preferred source on GoogleNovartis has entered a $5.7 billion licensing deal with Monte Rosa Therapeutics to develop immune-mediated disease drugs, boosting Monte Rosa's shares by 50%.
(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.
Under the agreement, Monte Rosa Therapeutics will receive an upfront payment of $120 million and could earn up to $5.7 billion in total, including milestone payments and royalties on future drug sales.
This marks Novartis’ second major deal this month, following an up-to-$5.2 billion deal with China's Argo Biopharmaceutical for experimental heart drugs.
Shares of Monte Rosa surged 50% in premarket trading after the announcement.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid)
The licensing deal is worth up to $5.7 billion, which includes milestone payments and royalties on future drug sales.
Monte Rosa Therapeutics will receive an upfront payment of $120 million as part of the agreement.
Shares of Monte Rosa surged 50% in premarket trading following the announcement of the deal.
Before this deal, Novartis signed an up-to-$5.2 billion agreement with China's Argo Biopharmaceutical for experimental heart drugs.
The drugs developed under this licensing deal will target immune-mediated diseases.
Explore more articles in the Headlines category
